Incidence of adverse events · first aid in patients with acute oral poisoning (not specified, tricyclic antidepressants, combinations of different drugs or yellow…
1 finding from 1 review
Withdrawals due to adverse events · patients with tension‐type headache
SSRIs or SNRIs showed no clear difference in withdrawals due to adverse events compared with other antidepressants (low certainty).
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion showed no clear difference in serious adverse events compared with placebo/no pharmacological treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion plus nicotine replacement therapy (NRT) showed no clear difference in serious adverse events compared with NRT alone (low certainty).
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion plus varenicline showed no clear difference in serious adverse events compared with varenicline alone (low certainty).
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Serious adverse events · children (4 to 18 years) with functional abdominal pain disorders
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Adverse events (at 12 weeks) · adults with insomnia
1 finding from 1 review
Overall adverse events 5 weeks · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes overall adverse events 5 weeks compared with placebo (very low certainty).
1 finding from 1 review
Overall rate of adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in overall rate of adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with the treatment of cocaine dependence
Amantidine showed no clear difference in adverse events as N of participants with at least one adverse event compared with antidepressants (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
Antidepressant showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
1 finding from 1 review
Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Withdrawals due to adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in discontinuation due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with panic disorder
TCA showed no clear difference in number of dropouts due to adverse events compared with MAOI (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with panic disorder
SSRIs showed no clear difference in number of dropouts due to adverse events compared with MAOIs (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with panic disorder
SSRIs showed no clear difference in number of dropouts due to adverse events compared with naSSAs (low certainty).
1 finding from 1 review